Correlation between RUNX3 expression of Colorectal Cancer and Its Clinical Characteristics: A Meta-Analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 DEJi ^1,2 , GUOTian-jiao ¹ , SUChang ¹ , ZHULin-lin ¹ , YANGJin-lin ¹ ,  WANGYi-ping ¹

1. Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, China;
2. Tibetan Hospital of Tibet Autonomous Region, Lhasa 850000, China;

Corresponding?author：

WANGYi-ping, Email: wyplm2012@163.com

Keywords：

RUNX3; Colorectal cancer; Systematic review; Meta-analysis; Case-control study

DOI：

10.7507/1672-2531.20140135

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the correlation between RUNX3 expression of colorectal cancer and its clinical characteristics. Methods Databases including PubMed, The Cochrane Library (Issue 9, 2013), EMbase, MEDLINE (Ovid), CNKI, VIP, WanFang Data and CBM were searched for collecting published international and domestic case-control studies on the correlation between RUNX3 expression of colorectal cancer and its clinical characteristics from the date of their establishment to October 1st, 2013. Two reviewers screened literature according to the inclusion and exclusion criteria, extracted data, and assessed the methodological quality of the included studies. Then, meta-analysis was performed using RevMan 5.2 software. Results A total of 7 case-control studies were included involving 804 cases in total (521 cases in colorectal cancer group and 383 cases in control group). The results of meta-analysis showed that, RUNX3 expression was lower in the colorectal cancer group than in the normal control group (OR=0.05, 95%CI 0.03 to 0.08, P < 0.000 01); higher in the moderately/highly-differentiated group than in the poorly differentiated group (OR=4.77, 95%CI 2.88 to 7.90, P < 0.000 01); higher in colorectal cancer with invasion depth on T₁-T₂ stage than in that on T₃-T₄ stage (OR=8.13, 95%CI 4.15 to 15.92, P < 0.000 01); and lower in the colorectal cancer accompanied with lymph node metastasis than that without lymph node metastasis (OR=0.23, 95%CI 0.14 to 0.36, P < 0.000 01), all with significant differences. No significant difference was found in RUNX3 expression between groups by age, sex and tumour location. Conclusion RUNX3 expression is notably correlated to colorectal cancer and its clinical characteristics. Due to the quantity and quality limitation of the included studies, the above conclusion still needs to be further proved by performing more high quality studies.

Citation： DEJi, GUOTian-jiao, SUChang, ZHULin-lin, YANGJin-lin, WANGYi-ping. Correlation between RUNX3 expression of Colorectal Cancer and Its Clinical Characteristics: A Meta-Analysis. Chinese Journal of Evidence-Based Medicine, 2014, 14(7): 806-812. doi: 10.7507/1672-2531.20140135 Copy

1.	Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA-Cancer J Clin, 2009, 59(4):225-249.
2.	Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA-Cancer J Clin, 2011, 61(2):69-90.
3.	陳光俠, 何曉華, 陸敬華, 等.舒林酸對結腸癌SW1116細胞生長的影響.浙江臨床醫學, 2010, 12(1):3-6.
4.	Lee Y M. Control of RUNX3 by histone methyltransferases. J Cell Biochem, 2011, 112(2):394-400.
5.	Bosman F T, Cameiro F, Hruban R H, et al. World health organization classification of tumours of the digestive system. Lyon:IARC Press, 2010.
6.	Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 3rd Symposium on Systematic Reviews:Beyond the Basics. 2000.
7.	葉盛前, 葉菲, 金銀姬, 等. RUNX3蛋白與Bcl-2家族蛋白在結腸癌中的表達及其意義.腫瘤學雜志, 2011, 17(12):893-896.
8.	汪砥, 鐘美佐. RUNX3蛋白在大腸癌中的表達及其與臨床化療療效關系探討.腫瘤藥學, 2011, 1(3):183-184.
9.	王殉, 王明林, 胡義奎. RUNX3蛋白在人結直腸癌中的表達及其臨床意義.胃腸病學, 2007, 12(7):414-416.
10.	嚴茂軍, 陸紅梅, 孫慶旭, 等. RUNX3基因甲基化在結直腸癌發生中的作用及與預后的關系.中華普通外科雜志, 2012, 27(008):664-667.
11.	李華, 黨榮良, 袁權利, 等.結腸癌組織中RUNX3, 突變型p53蛋白的表達變化及意義.山東醫藥, 2010, 50(026):56.
12.	肖開提, 阿不都, 哈德爾, 等.人結腸癌組織中RUNX3的表達意義.第四軍醫大學學報, 2008, 29(17):1618-1620.
13.	賈光輝, 薛軍, 趙秀芳, 等. RUNX3和ki-67在結直腸癌中的表達及其相關性.內蒙古醫學雜志, 2013, 45(5):524-528.
14.	Bangsow C, Rubins N, Glusman G, et al. The RUNX3 gene-sequence, structure and regulated expression. Gene, 2001, 279(2):221-232.
15.	張海元, 劉娟, 解庭波.肝細胞癌中RUNX3基因啟動子區甲基化研究.華中科技大學學報:醫學版, 2009, 38(1):23-26.
16.	Wei D, Gong W, Oh SC, et al. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Research, 2005, 65(11):4809-4816.
17.	Hiramatsu T, Osaki M, Ito Y, et al. Expression of RUNX3 protein in human esophageal mucosa and squamous cell carcinoma. Pathobiology, 2006, 72(6):316-324.
18.	Shima K, Morikawa T, Baba Y, et al. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes & Control, 2011, 22(2):301-309.
19.	Imamura Y, Hibi K, Koike M, et al. RUNX3 promoter region is specifically methylated in poorly-differentiated colorectal cancer. Anticancer Res, 2005, 25(4):2627-2630.
20.	Ku JL, Kang SB, Shin YK, et al. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene, 2004, 23(40):6736-6742.
21.	Peng Z, Tang H, Wang X, et al. Inhibition of the growth and metastasis of human colon cancer by restoration of RUNX3 expression in cancer cells. Int J Oncol, 2008, 33(5):979-984.
22.	何紹亞, 韓盛璽, 蔣仁發, 等. RUNX3基因甲基化及RUNX3蛋白表達在結腸癌發生中的意義.世界華人消化雜志, 2011, 19(17):1860-1863.
23.	Watanabe T, Kobunai T, Ikeuchi H, et al. RUNX3 copy number predicts the development of UC-associated colorectal cancer. Int J Oncol, 2011, 38(1):201-207.
24.	姜洪偉, 房學東, 張偉, 等.抑癌基因RUNX3基因在結直腸癌中的表達及臨床意義.現代中西醫結合雜志, 2011, 20(001):3-6.
25.	王蓓蓓. RUNX3蛋白在結直腸癌中的表達特點及意義.大連醫科大學, 2011.
26.	Subramaniam MM, Chan JY, Soong R, et al. RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis. Am J Gastroenterol, 2009, 104(2):426-436.
27.	Soong R, Shah N, Peh B K, et al. The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Brit J Cancer, 2009, 100(5):676-679.
28.	肖述兵, 彭碧華, 萬金龍, 等.原發性結腸癌組織RUNX3基因表達及臨床意義.浙江臨床醫學, 2012, 14(7):775-776.

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA-Cancer J Clin, 2009, 59(4):225-249.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA-Cancer J Clin, 2011, 61(2):69-90.
3. 陳光俠, 何曉華, 陸敬華, 等.舒林酸對結腸癌SW1116細胞生長的影響.浙江臨床醫學, 2010, 12(1):3-6.
4. Lee Y M. Control of RUNX3 by histone methyltransferases. J Cell Biochem, 2011, 112(2):394-400.
5. Bosman F T, Cameiro F, Hruban R H, et al. World health organization classification of tumours of the digestive system. Lyon:IARC Press, 2010.
6. Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 3rd Symposium on Systematic Reviews:Beyond the Basics. 2000.
7. 葉盛前, 葉菲, 金銀姬, 等. RUNX3蛋白與Bcl-2家族蛋白在結腸癌中的表達及其意義.腫瘤學雜志, 2011, 17(12):893-896.
8. 汪砥, 鐘美佐. RUNX3蛋白在大腸癌中的表達及其與臨床化療療效關系探討.腫瘤藥學, 2011, 1(3):183-184.
9. 王殉, 王明林, 胡義奎. RUNX3蛋白在人結直腸癌中的表達及其臨床意義.胃腸病學, 2007, 12(7):414-416.
10. 嚴茂軍, 陸紅梅, 孫慶旭, 等. RUNX3基因甲基化在結直腸癌發生中的作用及與預后的關系.中華普通外科雜志, 2012, 27(008):664-667.
11. 李華, 黨榮良, 袁權利, 等.結腸癌組織中RUNX3, 突變型p53蛋白的表達變化及意義.山東醫藥, 2010, 50(026):56.
12. 肖開提, 阿不都, 哈德爾, 等.人結腸癌組織中RUNX3的表達意義.第四軍醫大學學報, 2008, 29(17):1618-1620.
13. 賈光輝, 薛軍, 趙秀芳, 等. RUNX3和ki-67在結直腸癌中的表達及其相關性.內蒙古醫學雜志, 2013, 45(5):524-528.
14. Bangsow C, Rubins N, Glusman G, et al. The RUNX3 gene-sequence, structure and regulated expression. Gene, 2001, 279(2):221-232.
15. 張海元, 劉娟, 解庭波.肝細胞癌中RUNX3基因啟動子區甲基化研究.華中科技大學學報:醫學版, 2009, 38(1):23-26.
16. Wei D, Gong W, Oh SC, et al. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Research, 2005, 65(11):4809-4816.
17. Hiramatsu T, Osaki M, Ito Y, et al. Expression of RUNX3 protein in human esophageal mucosa and squamous cell carcinoma. Pathobiology, 2006, 72(6):316-324.
18. Shima K, Morikawa T, Baba Y, et al. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes & Control, 2011, 22(2):301-309.
19. Imamura Y, Hibi K, Koike M, et al. RUNX3 promoter region is specifically methylated in poorly-differentiated colorectal cancer. Anticancer Res, 2005, 25(4):2627-2630.
20. Ku JL, Kang SB, Shin YK, et al. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene, 2004, 23(40):6736-6742.
21. Peng Z, Tang H, Wang X, et al. Inhibition of the growth and metastasis of human colon cancer by restoration of RUNX3 expression in cancer cells. Int J Oncol, 2008, 33(5):979-984.
22. 何紹亞, 韓盛璽, 蔣仁發, 等. RUNX3基因甲基化及RUNX3蛋白表達在結腸癌發生中的意義.世界華人消化雜志, 2011, 19(17):1860-1863.
23. Watanabe T, Kobunai T, Ikeuchi H, et al. RUNX3 copy number predicts the development of UC-associated colorectal cancer. Int J Oncol, 2011, 38(1):201-207.
24. 姜洪偉, 房學東, 張偉, 等.抑癌基因RUNX3基因在結直腸癌中的表達及臨床意義.現代中西醫結合雜志, 2011, 20(001):3-6.
25. 王蓓蓓. RUNX3蛋白在結直腸癌中的表達特點及意義.大連醫科大學, 2011.
26. Subramaniam MM, Chan JY, Soong R, et al. RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis. Am J Gastroenterol, 2009, 104(2):426-436.
27. Soong R, Shah N, Peh B K, et al. The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Brit J Cancer, 2009, 100(5):676-679.
28. 肖述兵, 彭碧華, 萬金龍, 等.原發性結腸癌組織RUNX3基因表達及臨床意義.浙江臨床醫學, 2012, 14(7):775-776.

Chinese Journal of Evidence-Based Medicine

Correlation between RUNX3 expression of Colorectal Cancer and Its Clinical Characteristics: A Meta-Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content